デフォルト表紙
市場調査レポート
商品コード
1587790

臨床試験実施施設ネットワークの市場規模、シェア、動向分析レポート：治療分野別、フェーズ別、最終用途別、地域別、セグメント別予測、2025年～2030年

Clinical Trial Investigative Site Network Market Size, Share & Trends Analysis Report By Therapeutic Areas (Oncology, Cardiology), By Phase (Phase I, Phase II), By End Use, By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 120 Pages
納期
2～10営業日
カスタマイズ可能
臨床試験実施施設ネットワークの市場規模、シェア、動向分析レポート：治療分野別、フェーズ別、最終用途別、地域別、セグメント別予測、2025年～2030年
出版日: 2024年10月31日
発行: Grand View Research
ページ情報: 英文 120 Pages
納期: 2～10営業日
GIIご利用のメリット

  • 全表示

  • 概要
  • 図表
  • 目次
概要

臨床試験実施施設ネットワーク市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、臨床試験実施施設ネットワークの世界市場規模は2030年までに137億6,000万米ドルに達し、2025年から2030年までのCAGRは7.85％で拡大すると推定されています。

医薬品研究開発への投資の増加、新しい治療法に対する需要の増加、臨床試験の施設管理に関連する合併症は、業界の成長を促進する主な要因の一部です。過去5年間、臨床試験は一貫して増加しています。例えば、ClinicalTrials.govによると、2018年には262,298件以上の臨床試験が登録されたが、2022年9月時点では399,518件以上の臨床試験が登録されています。研究資金が改善されるにつれて、臨床試験はさらに成長すると予想されます。

これは、パンデミック後の業界の成長を促進すると予想されます。臨床研究に関連するコストを削減することに注目が集まっています。臨床試験実施施設ネットワークを雇用することで、規制機能をサポートし、参加者の登録を改善し、データ管理、品質保証を支援します。また、プロセスコンプライアンスを向上させ、各臨床試験におけるプロセスの問題を軽減し、より迅速な臨床試験の開始と臨床試験期間の短縮に貢献します。これらの要因が治験施設ネットワークの需要を支えています。各国政府は、税控除を提供することで研究開発を積極的に改善しようとしています。例えば、2022年1月、インド政府は研究開発における加重平均税額控除を最大200%まで提供すると表明しました。

このような取り組みにより、医薬品の研究開発活動が改善され、業界の成長が促進されることが期待されます。IQVIAのオンコロジー動向に関する報告書によると、がんの臨床試験は過去10年間増加し続けています。例えば、2011年には1,242件の臨床試験が登録され、2021年時点では2,335件の臨床試験が登録されています。がんの臨床試験数は、がんの有病率の増加により、さらに増加すると予想されます。このため、パンデミック後のがん臨床試験における治験施設ネットワークの需要が向上すると予想されます。

臨床試験実施施設ネットワーク市場レポート・ハイライト

  • 治療分野別では、がん分野が2024年に35.1%のシェアで市場を独占しました。がんを対象とした臨床試験件数の増加が、同分野の成長を支える主要因の1つです。
  • 第III相は他の相に比べて患者数が多く、治験施設ネットワークの需要を支えています。
  • 最終用途別では、CRO（医薬品開発業務受託機関）分野が予測期間中に最も速いCAGRを記録すると予測されています。
  • これは、治験施設ネットワークとCROの臨床試験における提携が増加しているためです。
  • アジア太平洋地域では臨床試験のアウトソーシングが増加しており、予測期間中に最も速いCAGRを記録すると予測されます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 臨床試験実施施設ネットワーク市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場見通し
  • 市場力学
    • 市場 促進要因分析
    • 市場抑制要因分析
  • 市場分析ツール
    • ポーターのファイブフォース分析
    • PESTEL分析
    • COVID-19の影響分析

第4章 臨床試験実施施設ネットワーク市場：フェーズの推定・動向分析

  • セグメントダッシュボード
  • 世界の臨床試験実施施設ネットワーク市場：フェーズ変動分析
  • 2018年から2030年までのフェーズ別臨床試験実施施設ネットワークの規模と動向分析
  • フェーズI
  • フェーズII
  • フェーズIII
  • フェーズIV

第5章 臨床試験実施施設ネットワーク市場：治療分野の推定・動向分析

  • セグメントダッシュボード
  • 世界の臨床試験実施施設ネットワーク市場：治療分野の変動分析
  • 2018年から2030年までの世界の臨床試験実施施設ネットワークの規模と動向分析：治療分野別
  • 腫瘍学
  • 心臓病学
  • 中枢神経系の症状
  • 疼痛管理
  • 内分泌
  • その他

第6章 臨床試験実施施設ネットワーク市場：最終用途の推定・動向分析

  • セグメントダッシュボード
  • 世界の臨床試験実施施設ネットワーク市場;最終用途変動分析
  • 世界の臨床試験実施施設ネットワークの規模と動向分析、最終用途別、2018～2030年
  • 製薬・バイオ医薬品企業
  • 医療機器企業
  • その他

第7章 臨床試験実施施設ネットワーク市場：地域の推定・動向分析

  • 地域別市場シェア分析、2023年および2030年
  • 地域市場ダッシュボード
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 企業分類
  • 企業市況分析、2024年
  • 企業プロファイル
    • ICON Plc
    • Velocity Clinical Research
    • IQVIA Inc.
    • Elligo Health Research
    • WCG Clinical
    • ClinChoice
    • Access Clinical Trials Inc.
    • FOMAT Medical Research, Inc.
    • SGS Societe Generale de Surveillance SA.
    • KV Clinical Research
    • SMO-Pharmina
    • Xylem Research LLP
    • The Aurum Institute
図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 4 Global Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 5 Global Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 6 Global Clinical Trial Investigative Site Network, by Region, 2018 - 2030 (USD Million)
  • Table 7 North America Clinical Trial Investigative Site Network, by Country, 2018 - 2030 (USD Million)
  • Table 8 North America Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 9 Global Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 10 North America Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 11 U.S. Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 12 U.S. Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 13 U.S. Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 14 Canada Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 15 Canada Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 16 Canada Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 17 Mexico Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 18 Mexico Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 19 Mexico Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 20 UK Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 21 UK Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 22 UK Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 23 Germany Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 24 Germany Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 25 Germany Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 26 France Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 27 France Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 28 France Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 29 Italy Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 30 Italy Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 31 Italy Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 32 Spain Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 33 Spain Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 34 Spain Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 35 Sweden Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 36 Sweden Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 37 Sweden Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 38 Norway Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 39 Norway Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 40 Norway Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 41 Denmark Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 42 Denmark Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 43 Denmark Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 44 India Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 45 India Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 46 India Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 47 China Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 48 China Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 49 China Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 50 Japan Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 51 Japan Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 52 Japan Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 53 India Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 54 India Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 55 India Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 56 Australia Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 57 Australia Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 58 Australia Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 59 Thailand Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 60 Thailand Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 61 Thailand Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 62 South Korea Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 63 South Korea Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 64 South Korea Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 65 Brazil Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 66 Brazil Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 67 Brazil Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 68 Argentina Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 69 Argentina Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 70 Argentina Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 71 Saudi Arabia Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 72 Saudi Arabia Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 73 Saudi Arabia Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 74 UAE Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 75 UAE Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 76 UAE Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 77 Kuwait Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 78 Kuwait Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 79 Kuwait Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1. Information Procurement
  • Fig. 2. Primary Research Pattern
  • Fig. 3. Market Research Approaches
  • Fig. 4. Value Chain-Based Sizing & Forecasting
  • Fig. 5. Market Formulation & Validation
  • Fig. 6. Clinical Trial Investigative Site Network, Market Segmentation
  • Fig. 7. Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 8. Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 9. Porter's Five Forces Analysis
  • Fig. 10. PESTEL Analysis
  • Fig. 11. Regional Marketplace: Key Takeaways
  • Fig. 12. Global Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 13. Global Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 14. Global Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 15. Global Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 16. Global Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 17. Global Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 18. Global Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 19. Global Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 20. Global Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 21. Global Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 22. Global Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 23. Global Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 24. Global Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 25. North America Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 26. North America Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 27. North America Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 28. North America Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 29. North America Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 30. North America Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 31. North America Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 32. North America Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 33. North America Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 34. North America Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 35. North America Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 36. North America Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 37. North America Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 38. U.S. Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 39. U.S. Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 40. U.S. Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 41. U.S. Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 42. U.S. Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 43. U.S. Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 44. U.S. Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 45. U.S. Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 46. U.S. Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 47. U.S. Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 48. U.S. Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 49. U.S. Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 50. U.S. Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 51. Canada Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 52. Canada Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 53. Canada Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 54. Canada Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 55. Canada Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 56. Canada Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 57. Canada Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 58. Canada Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 59. Canada Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 60. Canada Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 61. Canada Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 62. Canada Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 63. Canada Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 64. Mexico Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 65. Mexico Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 66. Mexico Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 67. Mexico Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 68. Mexico Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 69. Mexico Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 70. Mexico Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 71. Mexico Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 72. Mexico Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 73. Mexico Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 74. Mexico Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 75. Mexico Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 76. Mexico Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 77. Europe Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 78. Europe Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 79. Europe Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 80. Europe Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 81. Europe Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 82. Europe Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 83. Europe Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 84. Europe Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 85. Europe Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 86. Europe Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 87. Europe Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 88. Europe Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 89. Europe Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 90. UK Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 91. UK Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 92. UK Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 93. UK Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 94. UK Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 95. UK Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 96. UK Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 97. UK Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 98. UK Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 99. UK Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 100. UK Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 101. UK Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 102. UK Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 103. Germany Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 104. Germany Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 105. Germany Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 106. Germany Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 107. Germany Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 108. Germany Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 109. Germany Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 110. Germany Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 111. Germany Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 112. Germany Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 113. Germany Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 114. Germany Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 115. Germany Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 116. France Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 117. France Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 118. France Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 119. France Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 120. France Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 121. France Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 122. France Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 123. France Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 124. France Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 125. France Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 126. France Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 127. France Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 128. France Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 129. Spain Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 130. Spain Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 131. Spain Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 132. Spain Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 133. Spain Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 134. Spain Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 135. Spain Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 136. Spain Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 137. Spain Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 138. Spain Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 139. Spain Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 140. Spain Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 141. Spain Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 142. Italy Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 143. Italy Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 144. Italy Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 145. Italy Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 146. Italy Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 147. Italy Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 148. Italy Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 149. Italy Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 150. Italy Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 151. Italy Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 152. Italy Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 153. Italy Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 154. Italy Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 155. Denmark Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 156. Denmark Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 157. Denmark Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 158. Denmark Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 159. Denmark Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 160. Denmark Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 161. Denmark Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 162. Denmark Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 163. Denmark Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 164. Denmark Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 165. Denmark Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 166. Denmark Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 167. Denmark Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 168. Sweden Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 169. Sweden Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 170. Sweden Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 171. Sweden Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 172. Sweden Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 173. Sweden Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 174. Sweden Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 175. Sweden Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 176. Sweden Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 177. Sweden Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 178. Sweden Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 179. Sweden Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 180. Sweden Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 181. Norway Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 182. Norway Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 183. Norway Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 184. Norway Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 185. Norway Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 186. Norway Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 187. Norway Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 188. Norway Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 189. Norway Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 190. Norway Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 191. Norway Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 192. Norway Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 193. Norway Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 194. Asia Pacific Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 195. Asia Pacific Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 196. Asia Pacific Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 197. Asia Pacific Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 198. Asia Pacific Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 199. Asia Pacific Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 200. Asia Pacific Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 201. Asia Pacific Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 202. Asia Pacific Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 203. Asia Pacific Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 204. Asia Pacific Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 205. Asia Pacific Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 206. Asia Pacific Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 207. Japan Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 208. Japan Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 209. Japan Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 210. Japan Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 211. Japan Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 212. Japan Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 213. Japan Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 214. Japan Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 215. Japan Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 216. Japan Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 217. Japan Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 218. Japan Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 219. Japan Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 220. China Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 221. China Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 222. China Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 223. China Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 224. China Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 225. China Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 226. China Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 227. China Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 228. China Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 229. China Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 230. China Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 231. China Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 232. China Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 233. India Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 234. India Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 235. India Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 236. India Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 237. India Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 238. India Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 239. India Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 240. India Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 241. India Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 242. India Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 243. India Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 244. India Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 245. India Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 246. Australia Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 247. Australia Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 248. Australia Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 249. Australia Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 250. Australia Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 251. Australia Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 252. Australia Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 253. Australia Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 254. Australia Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 255. Australia Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 256. Australia Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 257. Australia Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 258. Australia Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 259. Thailand Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 260. Thailand Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 261. Thailand Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 262. Thailand Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 263. Thailand Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 264. Thailand Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 265. Thailand Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 266. Thailand Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 267. Thailand Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 268. Thailand Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 269. Thailand Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 270. Thailand Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 271. Thailand Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 272. South Korea Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 273. South Korea Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 274. South Korea Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 275. South Korea Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 276. South Korea Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 277. South Korea Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 278. South Korea Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 279. South Korea Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 280. South Korea Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 281. South Korea Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 282. South Korea Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 283. South Korea Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 284. South Korea Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 285. Latin America Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 286. Latin America Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 287. Latin America Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 288. Latin America Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 289. Latin America Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 290. Latin America Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 291. Latin America Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 292. Latin America Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 293. Latin America Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 294. Latin America Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 295. Latin America Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 296. Latin America Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 297. Latin America Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 298. Brazil Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 299. Brazil Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 300. Brazil Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 301. Brazil Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 302. Brazil Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 303. Brazil Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 304. Brazil Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 305. Brazil Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 306. Brazil Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 307. Brazil Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 308. Brazil Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 309. Brazil Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 310. Brazil Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
目次
Product Code: GVR-4-68039-986-6

Clinical Trial Investigative Site Network Market Growth & Trends:

The global clinical trial investigative site network market size is estimated to reach USD 13.76 billion by 2030, expanding at a CAGR of 7.85% from 2025 to 2030, according to a new report by Grand View Research, Inc. Growing investments in pharmaceutical R&D, increasing demand for new therapies and complications associated with site management of clinical trials are some of the major factors driving the growth of the industry. There has been a consistent rise the clinical trials in the last 5 years. For instance, according to ClinicalTrials.gov, over 262,298 trials were registered in 2018, whereas as of September 2022, over 399,518 trials were registered. The clinical trials are expected to grow even further as the funding for research improves.

This is expected to propel the growth of the industry post-pandemic. There is a growing focus on reducing the cost associated with clinical research. Hiring a clinical trial investigative site network supports the regulatory function, improves the enrollment of participants, assists in data management, and quality assurance. It increases process compliance, reduces process issues with each trial, and helps with faster trial initiations, and shorter trial timelines. These factors are supporting the demand for clinical investigative site networks. The governments are actively trying to improve R&D by providing tax deductions. For instance, in January 2022, the Indian government stated that it is providing a weighted average tax deduction of up to 200% in R&D.

Such initiatives are expected to improve the R&D activities on drugs and thus support industry growth. According to the IQVIA, report on oncology trends, clinical trials for cancer have been increasing for the last 10 years. For instance, in 2011, 1,242 trials were registered for cancer, and as of 2021, 2,335 trials were registered for cancer. The number of clinical trials for cancer is expected to rise even further owing to the growing prevalence of the disease. This is expected to improve the demand for clinical investigative site networks for cancer clinical trials post-pandemic.

Clinical Trial Investigative Site Network Market Report Highlights:

  • Based on therapeutic areas, the oncology segment dominated the market with a share of 35.1% in 2024. The growing number of clinical trials for cancer is one of the major factors supporting the segment growth
  • The phase III segment led the industry in 2024 with the maximum revenue share as this phase includes a greater number of patients than other phases, thus supporting the demand for clinical investigative site network
  • Based on end-use, the Contract Research Organizations (CROs) segment is anticipated to witness the fastest CAGR over the forecast perio
  • This is owing to the increasing number of partnerships among site networks and CROs for clinical studies
  • Asia Pacific is anticipated to register the fastest CAGR over the forecast period due to a rise in the outsourcing of clinical trials in this region

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity Flow Analysis
    • 1.6.2. Bottom-up Approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Abbreviations
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Clinical Trial Investigative Site Network Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing Prevalence of Chronic Diseases
      • 3.2.1.2. Increasing Technological Advancements
      • 3.2.1.3. Increasing Partnerships and Collaborations
      • 3.2.1.4. Expansion of Decentralized Trials
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Rising Costs of Clinical Trials
      • 3.2.2.2. Limited Awareness and Training
      • 3.2.2.3. Data Privacy Concerns
  • 3.3. Market Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Clinical Trial Investigative Site Network Market: Phase Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Clinical Trial Investigative Site Network Market; Phase Movement Analysis
  • 4.3. Global Clinical Trial Investigative Site Network Size & Trend Analysis, by Phase, 2018 to 2030 (USD Million)
  • 4.4. Phase I
    • 4.4.1. Phase I market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Phase II
    • 4.5.1. Phase II market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Phase III
    • 4.6.1. Phase III market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Phase IV
    • 4.7.1. Phase IV market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Clinical Trial Investigative Site Network Market: Therapeutic Areas Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Clinical Trial Investigative Site Network Market; Therapeutic Areas Movement Analysis
  • 5.3. Global Clinical Trial Investigative Site Network Size & Trend Analysis, by Therapeutic Areas, 2018 to 2030 (USD Million)
  • 5.4. Oncology
    • 5.4.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Cardiology
    • 5.5.1. Cardiology market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. CNS Conditions
    • 5.6.1. CNS Conditions market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Pain management
    • 5.7.1. Pain management market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Endocrine
    • 5.8.1. Endocrine market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Clinical Trial Investigative Site Network Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Clinical Trial Investigative Site Network Market; End Use Movement Analysis
  • 6.3. Global Clinical Trial Investigative Site Network Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 6.4. Pharmaceutical & Biopharmaceutical Companies
    • 6.4.1. Pharmaceutical & biopharmaceutical companies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Medical Device Companies
    • 6.5.1. Medical device companies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Clinical Trial Investigative Site Network Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. North America
    • 7.3.1. North America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Competitive scenario
      • 7.3.2.3. Regulatory framework
      • 7.3.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Competitive scenario
      • 7.3.3.3. Regulatory framework
      • 7.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Key country dynamics
      • 7.3.4.2. Competitive scenario
      • 7.3.4.3. Regulatory framework
      • 7.3.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Competitive scenario
      • 7.4.2.3. Regulatory framework
      • 7.4.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Competitive scenario
      • 7.4.3.3. Regulatory framework
      • 7.4.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. France
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Competitive scenario
      • 7.4.4.3. Regulatory framework
      • 7.4.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Italy
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Competitive scenario
      • 7.4.5.3. Regulatory framework
      • 7.4.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Spain
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Competitive scenario
      • 7.4.6.3. Regulatory framework
      • 7.4.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Denmark
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Competitive scenario
      • 7.4.7.3. Regulatory framework
      • 7.4.7.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Sweden
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Competitive scenario
      • 7.4.8.3. Regulatory framework
      • 7.4.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.9. Norway
      • 7.4.9.1. Key country dynamics
      • 7.4.9.2. Competitive scenario
      • 7.4.9.3. Regulatory framework
      • 7.4.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Japan
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Competitive scenario
      • 7.5.2.3. Regulatory framework
      • 7.5.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. China
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Competitive scenario
      • 7.5.3.3. Regulatory framework
      • 7.5.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. India
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Competitive scenario
      • 7.5.4.3. Regulatory framework
      • 7.5.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. Australia
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Competitive scenario
      • 7.5.5.3. Regulatory framework
      • 7.5.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. South Korea
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Competitive scenario
      • 7.5.6.3. Regulatory framework
      • 7.5.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.7. Thailand
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Competitive scenario
      • 7.5.7.3. Regulatory framework
      • 7.5.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Brazil
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Competitive scenario
      • 7.6.2.3. Regulatory framework
      • 7.6.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Competitive scenario
      • 7.6.3.3. Regulatory framework
      • 7.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Competitive scenario
      • 7.7.2.3. Regulatory framework
      • 7.7.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. Saudi Arabia
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Competitive scenario
      • 7.7.3.3. Regulatory framework
      • 7.7.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. UAE
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Competitive scenario
      • 7.7.4.3. Regulatory framework
      • 7.7.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. Kuwait
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Competitive scenario
      • 7.7.5.3. Regulatory framework
      • 7.7.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Company Market Position Analysis, 2024
  • 8.3. Company Profiles
    • 8.3.1. ICON Plc
      • 8.3.1.1. Company overview
      • 8.3.1.2. Financial performance
      • 8.3.1.3. Service benchmarking
      • 8.3.1.4. Strategic initiatives
    • 8.3.2. Velocity Clinical Research
      • 8.3.2.1. Company overview
      • 8.3.2.2. Financial performance
      • 8.3.2.3. Service benchmarking
      • 8.3.2.4. Strategic initiatives
    • 8.3.3. IQVIA Inc.
      • 8.3.3.1. Company overview
      • 8.3.3.2. Financial performance
      • 8.3.3.3. Service benchmarking
      • 8.3.3.4. Strategic initiatives
    • 8.3.4. Elligo Health Research
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Service benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. WCG Clinical
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Service benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. ClinChoice
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Service benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Access Clinical Trials Inc.
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Service benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. FOMAT Medical Research, Inc.
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Service benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. SGS Societe Generale de Surveillance SA.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Service benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. KV Clinical Research
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Service benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. SMO-Pharmina
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Service benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Xylem Research LLP
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Service benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. The Aurum Institute
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Service benchmarking
      • 8.3.13.4. Strategic initiatives